Overview
About HJB
HJB, a subsidiary of Transcenta Holding Limited, is dedicated to providing high quality, speedy and flexible CDMO services for large molecules. We apply and are continuously developing highly efficient technology platforms, operation strategy and manufacturing facilities for rapid development of effective biotherapeutics and for production at the lowest possible cost.
HJB has established sites in China and the US, both supported by a team of over 200 experienced process scientists, engineers and biological manufacturing experts.
The state-of-the-art Hangzhou Manufacturing GMP Facility exemplifies most advanced biological process technology and facility design. It employs Integrated Continuous Bioprocessing Platform and flexible T-BLOC modular facility to accelerate development and improve process and product control, while significantly decrease cost of goods.
HJB offers comprehensive CDMO services with global quality and regulatory standards. Services include Cell Line Development, Cell Banking, Process Development, Analytical Development, DS & DP Manufacturing, Product Release and Stability Testing, and Regulatory Support to meet our clients’ needs of clinical trials and IND filing in both China and US.
HJB has established sites in China and the US, both supported by a team of over 200 experienced process scientists, engineers and biological manufacturing experts.
The state-of-the-art Hangzhou Manufacturing GMP Facility exemplifies most advanced biological process technology and facility design. It employs Integrated Continuous Bioprocessing Platform and flexible T-BLOC modular facility to accelerate development and improve process and product control, while significantly decrease cost of goods.
HJB offers comprehensive CDMO services with global quality and regulatory standards. Services include Cell Line Development, Cell Banking, Process Development, Analytical Development, DS & DP Manufacturing, Product Release and Stability Testing, and Regulatory Support to meet our clients’ needs of clinical trials and IND filing in both China and US.